Loading organizations...
GenVault has raised $77.0M across 5 funding rounds.
GenVault has raised $77.0M in total across 5 funding rounds.
GenVault is a West Deptford, New Jersey-based commercial biorepository that provides secure storage, transport, and management solutions for biological materials. The company serves academic research institutes, pharmaceutical companies, biotech firms, and government agencies by safeguarding sensitive assets such as blood, tissues, DNA, vaccines, and laboratory chemicals. Operating from a shared campus featuring a purpose-built facility spanning more than 500,000 square feet, the organization maintains strict environmental controls for refrigerated, frozen, cryogenic, and ambient storage. The infrastructure is specifically designed to protect commercial bioinventory against temperature fluctuations, humidity, fire, water, power loss, human error, and natural disasters. With a workforce of approximately 100 employees, the firm operates alongside sister company DocuVault, which previously acquired Bayshore Records Management, and recently appointed Andrew Lee as its executive director. GenVault was founded in 2021 by Keith DiMarino.
GenVault has raised $77.0M in total across 5 funding rounds.
GenVault's investors include Domain Associates.
GenVault has raised $77.0M across 5 funding rounds. Most recently, it raised $13.0M Series B in June 2008.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2008 | $13M Series B | — | Domain Associates | Announced |
| Apr 1, 2007 | $18M Series U | — | Domain Associates | Announced |
| Mar 1, 2005 | $23M Series A | — | Domain Associates | Announced |
| Aug 1, 2003 | $13M Series A | — | Domain Associates | Announced |
| Mar 1, 2003 | $10M Series A | — | Domain Associates | Announced |
GenVault is a technology company specializing in secure, compliant biorepository and sample storage solutions for the life sciences, pharmaceutical, and healthcare industries.[3][4] It provides biosample workflow, transport, and storage services, including ambient, refrigerated, frozen, and cryogenic options, using advanced facilities to preserve DNA, proteins, RNA, and other biological materials at controlled temperatures without refrigeration where possible.[1][2][3] The company serves researchers, medical centers, academic institutions, pharma companies, and law enforcement by solving challenges in biosample management, such as degradation, space constraints, and compliance, enabling genomic medicine, discovery, and long-term research.[1][4][5] With a focus on freeing lab resources and ensuring sample integrity, GenVault demonstrates growth through partnerships like Diligent Pharma and scalable infrastructure supporting over 500,000 cu.ft. of storage.[3][4]
GenVault traces its roots to the leadership team behind DocuVault, a records management company with over 20 years of experience in secure storage of sensitive assets like government records, healthcare data, and cultural archives.[3] Founded around 2001 as GenVault Corporation in Carlsbad, California, it emerged amid the genomics revolution, addressing the surge in biosample collections—estimated at over 307 million U.S. specimens accumulating 20 million annually—for genetic-environment-disease correlations and personalized medicine.[1][5] Early innovation centered on a dry-state platform for room-temperature DNA preservation, extraction, recovery, and distribution, with plans to extend to proteins and RNA, marking pivotal traction in integrated biosample solutions.[1][5] The company raised $42.5M before being acquired, evolving into a specialized biorepository provider.[1]
GenVault rides the genomics and personalized medicine wave, where exploding biosample volumes—driven by research into genetics, drug response, and epigenetics—demand reliable, scalable storage beyond traditional freezers.[1][5] Timing aligns with life sciences' shift to secure, accessible biorepositories amid regulatory pressures (GxP) and innovation in biopharma/clinical trials, amplified by post-2000s genomic booms.[3][4][5] Market forces like rising sample accumulation (20M+ yearly in the U.S.), space/resource constraints in labs, and needs for room-temperature stability favor its dry-state tech and transport solutions, reducing costs and degradation risks.[1][2][5] It influences the ecosystem by enabling downstream breakthroughs in discovery, identification, and therapeutics, partnering with quality-focused firms to standardize biosample management.[4]
GenVault is poised to expand as biorepository demands grow with AI-driven genomics, precision medicine, and global biopharma scaling, potentially leveraging its acquisition history for tech integrations like advanced automation or AI tracking.[1][3] Trends such as decentralized trials, climate-resilient storage, and data-linked samples will shape its path, enhancing usability of "biological data" for faster R&D.[4] Its influence may evolve from storage provider to ecosystem enabler, powering irreplaceable assets in an era where sample integrity unlocks genomic innovation—echoing its founding mission to accelerate life sciences breakthroughs.[3][4]
